# CRISPR Therapeutics AG (CRSP): MoatMap facts

As of 13 Nov 2026. Research data, not investment advice.

As of 13 Nov 2026, the MoatMap Score for CRISPR Therapeutics AG (CRSP) is 11/100, ranked against 25,000+ stocks in 38 markets (Quality 23, Value 26, Momentum 36, each scored against its sector).

- MoatMap Score: 11/100, a percentile across 25,000+ stocks in 38 markets (100 is best).
- Quality 23, Value 26, Momentum 36: each a 0-100 percentile within Healthcare.
- Position: #23,825 overall, #2,243 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 42.62 USD on 12 Nov 2026.
- Insider filings, last 180 days: directors sold USD 5.1M.

Source: https://moatmap.ai/stock/CRSP
How the scores work: https://moatmap.ai/methodology
Does the score work? Each tenth of the ranking is tracked monthly: https://moatmap.ai/decile-tracker